Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Treasury Shares: 2021-2024

Historic Treasury Shares for Zevra Therapeutics (ZVRA) over the last 4 years, with Dec 2024 value amounting to $11.0 million.

  • Zevra Therapeutics' Treasury Shares changed negligibly% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $11.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Zevra Therapeutics reported Treasury Shares of $11.0 million as of FY2024, which was down 0.00% from $11.0 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Treasury Shares ranged from a high of $1.8 million in FY2024 and a low of $320,161 during FY2021.
  • In the last 3 years, Zevra Therapeutics' Treasury Shares had a median value of $665,739 in 2023 and averaged $1.0 million.
  • Data for Zevra Therapeutics' Treasury Shares shows a peak YoY skyrocketed of 167.80% (in 2022) over the last 5 years.
  • Over the past 4 years, Zevra Therapeutics' Treasury Shares (Yearly) stood at $2.8 million in 2021, then spiked by 167.80% to $7.5 million in 2022, then surged by 45.74% to $11.0 million in 2023, then remained steady at $11.0 million in 2024.